Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model

Magnetic Resonance in Medicine

Volumn 60, Issue 5, 2008, Pages 1056-1065

  Lebel, Réjean ^a   Jastrzȩbska, Beata ^a   Therriault, Hélène ^b   Cournoyer, Marie Michèle ^a   McIntyre, J Oliver ^c   Escher, Emanuel ^b   Neugebauer, Witold ^b   Paquette, Benoit ^b   Lepage, Martin ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Breast cancer; DCE MRI; In vivo detection; Matrix metalloproteinase; MC7 L1; Smart contrast agent; Solubility switch

Indexed keywords

ENZYME ACTIVITY; PEPTIDES; SOLUBILITY;

BREAST CANCER; CONTRAST AGENT; DCE-MRI; IN-VIVO; MATRIX METALLOPROTEINASES; MC7-L1;

TUMORS;

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GELATINASE A; PROTEINASE MODULATED CONTRAST AGENT 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG SOLUBILITY; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DEGRADATION; WILD TYPE;

EID: 55749111198     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21741     Document Type: Article

References (28)

1. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007;8:63-74.
2. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26.
3. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856-1862.
4. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005;87:287-297.
5. Xu X, Wang Y, Chen Z, Sternlicht MD, Hidalgo M, Steffensen B. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res 2005;65:130-136.
6. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
7. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, Trudel D. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006;8:R28.
8. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
9. Overall CM, Kleifeld O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-239.
10. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001;221:523-529.
11. McIntyre JO, Fingleton B, Wells KS, Piston DW, Lynch CC, Gautam S, Matrisian LM. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J 2004;377:617-628.
12. Louie AY, Hüber MM, Ahrens ET, Rothbächer U, Moats R, Jacobs RE, Fraser SE, Meade TJ. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18:321-325.
13. Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC, Pépin C, Gore JC, Matrisian LM, McIntyre JO. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel MRI contrast agent with a solubility switch. Mol Imaging 2007;6:393-403.
14. Lanari C, Lüthy I, Lamb CA, Fabris V, Paganos E, Helguero LA, Sanjuan N, Merani S, Molinolo AA. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: In vivo and in vitro effects of estrogens and progestins. Cancer Res 2001;61:293-302.
15. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;107:222-239.
16. Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA 2001;7:1509-1521.
17. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005;65:3193-3199.
18. Paquette B, Bisson M, Therriault H, Lemay R, Pare M, Banville P, Cantin AM. Activation of matrix metalloproteinase-2 and -9 by 2- and 4-hydroxyestradiol. J Steroid Biochem Mol Biol 2003;87:65-73.
19. Albini A, D'Agostini F, Giunciuglio D, Paglieri I, Balansky R, De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 1995;61:121-129.
20. Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, Smith JW. A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem 2002;277:4485-4491.
21. Lauer-Fields JL, Sritharan T, Stack MS, Nagase H, Fields GB. Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem 2003;278:18140-18145.
22. Fields GB, Van Wart HE, Birkedal-Hansen H. Sequence specificity of human skin fibroblast collagenase. evidence for the role of collagen structure in determining the collagenase cleavage site. J Biol Chem 1987;262:6221-6226.
23. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vétek G, Pályka I, Springer CS. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000;44:563-574.
24. Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol 2002;28:24-29.
25. Mook ORF, Frederiks WM, Van Noorden CJF. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004;1705:69-89.
26. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-221.
27. Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC, Gore JC, Matrisian LM, McIntyre JO. Novel solubility switch contrast agents: in vivo detection of MMP-7 activity. In: Proceedings of the 15th Annual Meeting of ISMRM, Berlin, Germany, 2007 (Abstract 1167).
28. Stanisz GJ, Henkelman RM. Gd-DTPA relaxivity depends on macromolecular content. Magn Reson Med 2000;44:665-667.